Our work has three main objectives: (a) comparing, in a “real-world” setting, the hospitalization rates of various medical conditions in T2DM patients on home therapy with GLP-1 RAs or DPP-4is (either alone or in combination with other antidiabetic drugs) versus those on home therapy with different antidiabetic agents and/or insulin; (b) comparing the length of hospital stays between the two groups; and (c) calculating the mortality rates (all-cause and COVID-19-related mortality) of subjects with diabetes in the different groups. This evidence concerns the gene INS and COVID-19.